MX2009010064A - Metodos y composiciones para modular la actividad biologica de las citocinas il-17f/il-17a. - Google Patents
Metodos y composiciones para modular la actividad biologica de las citocinas il-17f/il-17a.Info
- Publication number
- MX2009010064A MX2009010064A MX2009010064A MX2009010064A MX2009010064A MX 2009010064 A MX2009010064 A MX 2009010064A MX 2009010064 A MX2009010064 A MX 2009010064A MX 2009010064 A MX2009010064 A MX 2009010064A MX 2009010064 A MX2009010064 A MX 2009010064A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- specific
- signaling
- disorders
- airway inflammation
- Prior art date
Links
- 102000013691 Interleukin-17 Human genes 0.000 title abstract 25
- 108050003558 Interleukin-17 Proteins 0.000 title abstract 23
- 238000000034 method Methods 0.000 title abstract 8
- 230000004071 biological effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 208000037883 airway inflammation Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000011664 signaling Effects 0.000 abstract 3
- 101000998145 Mus musculus Interleukin-17A Proteins 0.000 abstract 2
- 101000998150 Mus musculus Interleukin-17F Proteins 0.000 abstract 2
- 206010052779 Transplant rejections Diseases 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000000833 heterodimer Substances 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 238000010172 mouse model Methods 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 230000019491 signal transduction Effects 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La presente invención proporciona un IL-17F/IL-17A de ratón, novedoso, y proporciona además usos de tal IL17F/IL-17A de ratón en la caracterización del heterodírnero de IL-17F/IL-17A. La presente invención también está relacionada con los polinucleótidos y polipéptidos de la ruta de señalización de IL-17F/IL-17A, y ubicar como objetivo la ruta de señalización de IL-17F/IL-17A en los métodos de tratamiento de los trastornos asociados con IL-17F/IL-17A. La invención proporciona así métodos de uso de un heterodirnero de IL-17F/IL-17A aislado, por ejemplo, en un modelo de ratón de la inflamación de las vías respiratorias, y moduladores de IL-17F/IL-17A selectivos o específicos (por ejemplo, los agonistas de señalización o los antagonistas de señalización (por ejemplo, los anticuerpos antagonistas específicos o selectivos, las moléculas pequeñas antagonistas específicas o selectivas, etc.)). La invención también proporciona métodos de selección para los compuestos capaces de modular la actividad biológica de IL-17F/IL-17A, por ejemplo los antagonistas de señalización de IL-17F/IL-17A (por ejemplo, utilizando el modelo de ratón de la inflamación de las vías respiratorias), así como a métodos de identificación de que si el modulador de IL-17F/IL-17A es un modulador de IL-17F/IL-17A específico. La invención también está dirigida a nuevos métodos de diagnóstico, pronóstico, verificación, prevención, y/o tratamiento de los trastornos asociados con IL-17F/IL-17A, incluyendo, pero sin estar limitado a, los trastornos inflamatorios (por ejemplo la artritis (incluyendo la artritis reumatoide), psoriasis, lupus eritematoso sistémico, y esclerosis múltiple), enfermedades respiratorias (por ejemplo, la inflamación de las vías respiratorias, enfermedad pulmonar obstructiva crónica, fibrosis quística, asma, alergia), el rechazo de trasplantes (incluyendo el rechazo de trasplantes de órganos sólidos), y los trastornos o enfermedades inflamatorias del intestino (por ejemplo, colitis ulcerativa, enfermedad de Crohn). La presente invención está dirigida además a nuevas substancias terapéuticas y objetivos terapéuticos identificados por los métodos de selección de la invención, y a los usos de tales substancias terapéuticas en los métodos de tratamiento y prevención de los trastornos asociados con IL-17F/IL-17A.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92059107P | 2007-03-28 | 2007-03-28 | |
| US92217507P | 2007-04-05 | 2007-04-05 | |
| PCT/US2008/058735 WO2008121865A1 (en) | 2007-03-28 | 2008-03-28 | Methods and compositions for modulating il-17f/il-17a biological activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009010064A true MX2009010064A (es) | 2009-10-12 |
Family
ID=39639634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009010064A MX2009010064A (es) | 2007-03-28 | 2008-03-28 | Metodos y composiciones para modular la actividad biologica de las citocinas il-17f/il-17a. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20080241130A1 (es) |
| EP (1) | EP2126585A1 (es) |
| JP (1) | JP2010524850A (es) |
| AR (1) | AR066401A1 (es) |
| CA (1) | CA2680701A1 (es) |
| CL (1) | CL2008000883A1 (es) |
| MX (1) | MX2009010064A (es) |
| PA (1) | PA8773801A1 (es) |
| TW (1) | TW200902064A (es) |
| WO (1) | WO2008121865A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200641353A (en) * | 2005-02-14 | 2006-12-01 | Wyeth Corp | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
| AR075998A1 (es) * | 2009-04-01 | 2011-05-11 | Genentech Inc | Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit |
| JP5913103B2 (ja) * | 2009-09-14 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 |
| WO2011140484A1 (en) * | 2010-05-06 | 2011-11-10 | Singulex, Inc | Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis |
| CN103384682B (zh) | 2011-01-14 | 2017-04-12 | Ucb医药有限公司 | 结合il‑17a和il‑17f的抗体分子 |
| EP2809660B1 (en) | 2012-02-02 | 2016-01-20 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating il-17 |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| CN105420237A (zh) * | 2015-09-08 | 2016-03-23 | 中国农业科学院兰州兽医研究所 | 靶向抑制小鼠白细胞介素17A基因的序列siRNA-180 |
| JP6931648B2 (ja) * | 2015-10-27 | 2021-09-08 | ユーシービー バイオファルマ エスアールエル | 抗ｉｌ−１７ａ／ｆ抗体を用いた治療方法 |
| US20230167497A1 (en) * | 2020-04-30 | 2023-06-01 | Xiaohua Xue | Methods of identifying modulators of the il-17 pathway |
| CN117843801B (zh) * | 2023-12-29 | 2024-08-02 | 北京贝来药业有限公司 | 以白介素家族成员为靶点的新型抗体以及下游产品 |
| CN117843803B (zh) * | 2023-12-29 | 2024-11-29 | 北京贝来药业有限公司 | 串联单域抗体及其在疾病治疗中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737323A (en) * | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5830877A (en) * | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
| US5484909A (en) * | 1993-09-10 | 1996-01-16 | Amoco Corporation | Nucleic acid probes for the detection of bacteria of the genera Pediococcus and Lactobacillus and methods for the detection of the bacterial agents causing spoilage of beer |
| US5399677A (en) * | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
| US5516964A (en) * | 1994-01-21 | 1996-05-14 | Sun Company, Inc. (R&M) | Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal |
| DK0817847T4 (da) * | 1995-03-23 | 2009-10-05 | Immunex Corp | IL-17-receptor |
| US6902735B1 (en) * | 1995-07-19 | 2005-06-07 | Genetics Institute, Llc | Antibodies to human IL-17F and other CTLA-8-related proteins |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| US6074849A (en) * | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| DE69721548T2 (de) * | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| AU9482498A (en) * | 1997-09-17 | 1999-04-05 | Human Genome Sciences, Inc. | Interleukin-17 receptor-like protein |
| US6350892B1 (en) * | 1997-09-23 | 2002-02-26 | Bristol-Myers Squibb Company | Trifluoromethyl ketone analogs as selective cPLA2 inhibitors |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US20040043397A1 (en) * | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| MXPA03003407A (es) * | 2000-10-18 | 2004-05-04 | Immunex Corp | Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. |
| US20030133939A1 (en) * | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) * | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20040058445A1 (en) * | 2001-04-26 | 2004-03-25 | Ledbetter Jeffrey Alan | Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB |
| US20070160576A1 (en) * | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
| EP1641822B1 (en) * | 2003-07-08 | 2013-05-15 | Genentech, Inc. | Il-17 a/f heterologous polypeptides and therapeutic uses thereof |
| US7910540B2 (en) * | 2004-06-10 | 2011-03-22 | Zymogenetics, Inc. | Soluble ZcytoR14, anti-ZcytoR14 antibodies and binding partners and methods of using in inflammation |
| US20060039902A1 (en) * | 2004-08-05 | 2006-02-23 | Young Deborah A | Antagonizing interleukin-21 receptor activity |
| TW200641353A (en) * | 2005-02-14 | 2006-12-01 | Wyeth Corp | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor |
-
2008
- 2008-03-27 CL CL200800883A patent/CL2008000883A1/es unknown
- 2008-03-27 TW TW097110997A patent/TW200902064A/zh unknown
- 2008-03-28 WO PCT/US2008/058735 patent/WO2008121865A1/en not_active Ceased
- 2008-03-28 AR ARP080101300A patent/AR066401A1/es unknown
- 2008-03-28 US US12/057,778 patent/US20080241130A1/en not_active Abandoned
- 2008-03-28 MX MX2009010064A patent/MX2009010064A/es not_active Application Discontinuation
- 2008-03-28 CA CA002680701A patent/CA2680701A1/en not_active Abandoned
- 2008-03-28 PA PA20088773801A patent/PA8773801A1/es unknown
- 2008-03-28 EP EP08744665A patent/EP2126585A1/en not_active Withdrawn
- 2008-03-28 JP JP2010501267A patent/JP2010524850A/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008121865A1 (en) | 2008-10-09 |
| CA2680701A1 (en) | 2008-10-09 |
| CL2008000883A1 (es) | 2008-10-03 |
| TW200902064A (en) | 2009-01-16 |
| EP2126585A1 (en) | 2009-12-02 |
| PA8773801A1 (es) | 2008-11-19 |
| JP2010524850A (ja) | 2010-07-22 |
| AR066401A1 (es) | 2009-08-19 |
| US20080241130A1 (en) | 2008-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009010064A (es) | Metodos y composiciones para modular la actividad biologica de las citocinas il-17f/il-17a. | |
| TW200641353A (en) | Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor | |
| HRP20171176T1 (hr) | C5ar antagonisti | |
| MY153979A (en) | Substituted piperidino-dihydrothienopyrimidine | |
| MX337352B (es) | Nuevos agentes anti-inflamatorios. | |
| NO20074961L (no) | Imidazopyridazinforbindelser | |
| WO2002070509A8 (en) | Antagonists of mcp-1 function and methods of use thereof | |
| EA200802020A1 (ru) | Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1 | |
| SV2009002917A (es) | Derivados de 3-alquilazetidina sustituidos con heterociclos | |
| WO2007102883A3 (en) | Chemical compounds | |
| WO2008060814A3 (en) | ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF | |
| Delgado et al. | Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors | |
| WO2005124358A3 (en) | Diagnosis and treatment of siglec-6 associated diseases | |
| WO2005095973A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) | |
| WO2005050225A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) | |
| WO2005040825A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20) | |
| WO2005103702A3 (en) | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2) | |
| WO2005095972A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor etb (etb) | |
| WO2005040211A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1) | |
| WO2005059546A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35) | |
| WO2009151518A3 (en) | Methods and compositions for predicting development of atopic diseases | |
| ATE539159T1 (de) | Genetische varianten von menschlicher inositolpolyphosphat-4-phosphatase typ i (inpp4a) mit eignung zur vorhersage und therapie immunologischer erkrankungen | |
| WO2005040822A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25) | |
| WO2004104577A3 (en) | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4) | |
| WO2005103711A3 (en) | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |